Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
OtherPractice

Melatonin for children with autism spectrum disorder

Tyler Yan and Ran D. Goldman
Canadian Family Physician March 2020; 66 (3) 183-185;
Tyler Yan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ran D. Goldman
MD FRCPC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rgoldman@cw.bc.ca
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

Question I have several patients with autism spectrum disorder (ASD) who experience difficulties with sleep, affecting the quality of life of both the child and the family. Is melatonin an effective treatment for sleep problems in children with this condition?

Answer Autism spectrum disorder is prevalent among children in Canada and globally, with most affected children experiencing troubles with sleep. Behavioural therapy is the first-line treatment for sleep problems in children with ASD, and melatonin has been reported to be effective and safe in this population as an alternative or adjunctive treatment. A new pediatric, prolonged-release formulation of melatonin is not yet available in Canada, but initial studies in Europe have indicated that it is a potentially effective treatment for sleep problems in children with ASD.

Autism spectrum disorder (ASD), characterized by persistent deficits in social interactions with repetitive and restricted behaviour patterns,1 is estimated to affect up to 1.7% of children worldwide.2,3 According to a 2018 report by the Public Health Agency of Canada, which included almost 2 million participants (40% of Canada’s total population of those aged 5 to 17), approximately 1 in 66 Canadian children are diagnosed with ASD.4

Sleep problems with ASD

The prevalence of sleep abnormalities is as high as 60% to 86% in children with ASD,5 including complaints of early waking, poor sleep efficiency, somnambulism, and prolonged sleep-onset latency.6 Inadequate sleep can often cause excessive daytime sleepiness, leading to impaired daytime functioning and reduced cognitive abilities.7

Among 529 children aged 2 to 5 years from California, 53% of parents reported their children with ASD had at least 1 sleep problem “frequently” or “always” compared with 32% of parents with children without ASD (P < .0001).8 This translated to 21% of parents in the ASD group reporting that their child’s tricky sleep habits affected the child’s daily function and 23% reporting that it affected the family’s daily function (compared with 1.2% and 2.5%, respectively, in the non-ASD group),8 statistically significantly affecting the family’s quality of life.

Melatonin

The hormone melatonin is synthesized primarily by the pineal gland through regulation by the hypothalamic suprachiasmatic nucleus.9 As one of the primary modulators of the sleep-wake cycle, melatonin follows a circadian pattern of regulation, peaking in concentration at night with conversely low levels during the day.9 As a result, nighttime administration of melatonin has emerged as a common choice for treating insomnia in both children and adults.10,11

In its exogenous form, melatonin is considered a “natural health product” by Health Canada and is currently only recommended for use in adults.12 Use of melatonin is considered “off label” for the treatment of sleep problems in children and adolescents.13

Low melatonin levels in ASD

While the exact mechanisms of sleep disturbances in children with ASD remain unclear and are likely multifactorial, abnormalities in melatonin regulatory pathways might be a key contributor to the high prevalence of sleeping disorders in this population.5,14 In a systematic review of 9 trials with more than 800 participants, 7 trials reported lower concentrations of melatonin or melatonin metabolites in children and adults with ASD compared with healthy controls.15 Notably, the largest of these studies (n = 505) reported that 65% of participants with ASD had low melatonin (< 50% of mean control melatonin concentrations).16

Melatonin treatment for ASD

The current first-line approach to sleep abnormalities in children with ASD is behavioural interventions such as sleep hygiene education and positive reinforcement of adaptive sleep behaviour, as recommended by the Sleep Committee of the Autism Treatment Network in Canada and the United States.17 However, sleep management in children with ASD is difficult, with only 25% responding to behavioural interventions.18 If behavioural therapy fails, pharmacotherapy is often pursued, with melatonin having the greatest body of evidence among potential medications.17

In a meta-analysis of 5 small randomized controlled trials with a total of 96 children, treatment with immediate-release melatonin increased sleep duration by an average of 73 minutes and decreased sleep onset latency by an average of 66 minutes when compared with pre-melatonin treatment.15 Duration of melatonin treatment ranged from 14 days to more than 4 years, and minimal to no side effects were reported in these studies.15

Among 160 children from Italy, melatonin (3 mg) in combination with cognitive-behavioural therapy was the most effective in reducing insomnia when compared with each intervention separately.19 Notably, 63% of the combination-treatment group achieved a clinically significant change after 12 weeks (> 85% sleep efficiency, calculated as the ratio of total sleep time [TST] to total time in bed) compared with only 46% (P < .001) and 10% (P < .001) of those in the melatonin-only and cognitive-behavioural therapy–only groups, respectively.19 No adverse events were reported and none of the parents reported a loss of response to the melatonin during the 12-week period.19

A subsequent meta-synthesis of 8 reviews compared various sleep interventions for children with ASD and reported that melatonin and behavioural interventions were the most effective treatment options.6 The 2018 guidelines by the British Association for Psychopharmacology recommend melatonin in combination with a behavioural intervention as the treatment of choice for sleep problems in this population.20

In an open-label study of 24 children with ASD, melatonin was reported to improve autistic behavioural impairments in addition to the expected improvements in sleep.21 Fourteen weeks of melatonin treatment resulted in reduced withdrawal behaviour, as 66% of parents reported their child’s behaviour was withdrawn at the end of the study compared with 72% before treatment (according to the Child Behavior Checklist; P < .0001).21 Melatonin also improved both stereotypic and compulsive repetitive behaviour, with a reported incidence of 5.2% and 4.5%, respectively, after treatment compared with 6.6% and 7.1%, respectively, before treatment (measured with the Repetitive Behavior Scale; P = .008 and P < .0001, respectively).21 These findings suggest a potential role for melatonin in improving core and associated symptoms of ASD while concurrently improving sleep outcomes.21

Prolonged-release melatonin

Given the short half-life (20 to 50 min) of immediate-release melatonin, one might consider a prolonged-release formulation.22–24 A new pediatric, prolonged-release melatonin minitablet (PedPRM), currently available only in Germany, Finland, Norway, Iceland, Switzerland, the United Kingdom, and Italy, is an easily swallowed tablet22 designed to mimic the endogenous releasing pattern of the hormone and sustain plasma melatonin levels for up to 8 to 10 hours.25

Among 125 children with ASD (2 to 17.5 years of age), 69% of participants treated with PedPRM for 13 weeks (2 mg, increased to 5 mg after 3 weeks if the patient did not improve from baseline by at least 60 minutes in shortened sleep latency [SL] or increased TST) achieved clinically significant responses (increased TST by 45 min or decreased SL by 15 min or both) compared with 39% in the placebo group (P = .001, number needed to treat of 3.38).22 In an open-label follow-up study, 76% (95 of 125) of these children, regardless of their initial randomization group, continued with PedPRM treatment (2, 5, or 10 mg/day) for an additional 39 weeks.23 After the full 52-week period, 76% of participants had at least 60 minutes more sleep compared with baseline in TST, improved SL, or both.23 The most frequent treatment-related adverse events were fatigue (5.3%) and mood swings (3.2%); no serious treatment-related adverse events were reported.23 PedPRM appears to be an efficacious and safe option for children with ASD, although more clinical data are needed to assess long-term therapy.22,23

Conclusion

Sleep abnormalities are common among children with ASD, affecting both the child’s and the family’s daily function. Melatonin has demonstrated efficacy both independently and in combination with behavioural therapy in improving sleep with minimal side effects. A new pediatric, prolonged-released formulation of melatonin has shown promise in initial clinical trials but has yet to be made available in Canada and requires more research on its long-term efficacy and safety in children with ASD.

Notes

Child Health Update is produced by the Pediatric Research in Emergency Therapeutics (PRETx) program (www.pretx.org) at the BC Children’s Hospital in Vancouver, BC. Mr Yan is a member and Dr Goldman is Director of the PRETx program. The mission of the PRETx program is to promote child health through evidence-based research in therapeutics in pediatric emergency medicine.

Do you have questions about the effects of drugs, chemicals, radiation, or infections in children? We invite you to submit them to the PRETx program by fax at 604 875-2414; they will be addressed in future Child Health Updates. Published Child Health Updates are available on the Canadian Family Physician website (www.cfp.ca).

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. American Psychiatric Association,
    2. American Psychiatric Association DSM-5 Task Force
    . Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
  2. 2.↵
    1. Baxter AJ,
    2. Brugha TS,
    3. Erskine HE,
    4. Scheurer RW,
    5. Vos T,
    6. Scott JG
    . The epidemiology and global burden of autism spectrum disorders. Psychol Med 2015;45(3):601-13. Epub 2014 Aug 11.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Baio J,
    2. Wiggins L,
    3. Christensen DL,
    4. Maenner MJ,
    5. Daniels J,
    6. Warren Z,
    7. et al
    . Prevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2014. MMWR Morb Mortal Wkly Rep 2018;67(6):1-23. Errata in: MMWR Morb Mortal Wkly Rep 2018;67(19):564, MMWR Morb Mortal Wkly Rep 2018;67(45):1280.
    OpenUrlPubMed
  4. 4.↵
    1. Ofner M,
    2. Coles A,
    3. Decou ML,
    4. Do MT,
    5. Bienek A,
    6. Snider J,
    7. et al
    . Autism spectrum disorder among children and youth in Canada 2018. A report of the National Autism Spectrum Disorder Surveillance System. Ottawa, ON: Public Health Agency of Canada; 2018.
  5. 5.↵
    1. Souders MC,
    2. Zavodny S,
    3. Eriksen W,
    4. Sinko R,
    5. Connell J,
    6. Kerns C,
    7. et al
    . Sleep in children with autism spectrum disorder. Curr Psychiatry Rep 2017;19(6):34.
    OpenUrl
  6. 6.↵
    1. Cuomo BM,
    2. Vaz S,
    3. Lee EAL,
    4. Thompson C,
    5. Rogerson JM,
    6. Falkmer T
    . Effectiveness of sleep-based interventions for children with autism spectrum disorder: a meta-synthesis. Pharmacotherapy 2017;37(5):555-78.
    OpenUrl
  7. 7.↵
    1. Richdale AL,
    2. Schreck KA
    . Sleep problems in autism spectrum disorders: prevalence, nature, and possible biopsychosocial aetiologies. Sleep Med Rev 2009;13(6):403-11. Epub 2009 Apr 24.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Krakowiak P,
    2. Goodlin-Jones B,
    3. Hertz-Picciotto I,
    4. Croen L,
    5. Hansen R
    . Sleep problems in children with autism spectrum disorders, developmental delays, and typical development: a population-based study. J Sleep Res 2008;17(2):197-206. Erratum in: J Sleep Res 2012;21(2):231.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Owens JA,
    2. Moturi S
    . Pharmacologic treatment of pediatric insomnia. Child Adolesc Psychiatr Clin N Am 2009;18(4):1001-16.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Pandi-Perumal SR,
    2. Srinivasan V,
    3. Spence DW,
    4. Cardinali DP
    . Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs 2007;21(12):995-1018.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Johnson KP,
    2. Malow BA
    . Assessment and pharmacologic treatment of sleep disturbance in autism. Child Adolesc Psychiatr Clin N Am 2008;17(4):773-85, viii.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Cummings C,
    2. Canadian Paediatric Society,
    3. Community Paediatrics Committee
    . Melatonin for the management of sleep disorders in children and adolescents. Paediatr Child Health 2012;17(6):331-3.
    OpenUrl
  13. 13.↵
    1. Health Canada
    . Drugs and health products. Monograph: melatonin - sublingual. Ottawa, ON: Health Canada; 2018. Available from: http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=137&lang=eng. Accessed 2019 Aug 15.
  14. 14.↵
    1. Tordjman S,
    2. Najjar I,
    3. Bellissant E,
    4. Anderson GM,
    5. Barburoth M,
    6. Cohen D,
    7. et al
    . Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci 2013;14(10):20508-42.
    OpenUrlCrossRef
  15. 15.↵
    1. Rossignol DA,
    2. Frye RE
    . Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011;53(9):783-92. Epub 2011 Apr 19.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Melke J,
    2. Botros HG,
    3. Chaste P,
    4. Betancur C,
    5. Nygren G,
    6. Anckarsäter H,
    7. et al
    . Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry 2008;13(1):90-8. Epub 2007 May 15.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Malow BA,
    2. Byars K,
    3. Johnson K,
    4. Weiss S,
    5. Bernal P,
    6. Goldman SE,
    7. et al
    . A practice pathway for the identification, evaluation, and management of insomnia in children and adolescents with autism spectrum disorders. Pediatrics 2012;130(Suppl 2):S106-24.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Gringas P,
    2. Gamble C,
    3. Jones AP,
    4. Wiggs L,
    5. Williamson PR,
    6. Sutcliffe A,
    7. et al
    . Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial. BMJ 2012;345:e6664. Erratum in: BMJ 2012;345:e8409.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Cortesi F,
    2. Giannotti F,
    3. Sebastiani T,
    4. Panunzi S,
    5. Valente D
    . Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res 2012;21(6):700-9. Epub 2012 May 22.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Howes OD,
    2. Rogdaki M,
    3. Findon JL,
    4. Wichers RH,
    5. Charman T,
    6. King BH,
    7. et al
    . Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. J Psychopharmacol 2018;32(1):3-29. Epub 2017 Dec 14.
    OpenUrl
  21. 21.↵
    1. Malow B,
    2. Adkins KW,
    3. McGrew SG,
    4. Wang LL,
    5. Goldman SE,
    6. Fawkes D,
    7. et al
    . Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord 2012;42(8):1729-37.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Gringas P,
    2. Nir T,
    3. Breddy J,
    4. Frydman-Marom A,
    5. Findling RL
    . Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2017;56(11):948-957.e4. Epub 2017 Sep 19.
    OpenUrlPubMed
  23. 23.↵
    1. Maras A,
    2. Schroder CM,
    3. Malow BA,
    4. Findling RL,
    5. Breddy J,
    6. Nir T,
    7. et al
    . Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Child Adolesc Psychopharmacol 2018;28(10):699-710.
    OpenUrl
  24. 24.↵
    1. De Leersnyder H,
    2. Zisapel N,
    3. Laudon M
    . Prolonged-release melatonin for children with neurodevelopmental disorders. Pediatr Neurol 2011;45(1):23-6.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Schroder CM,
    2. Malow BA,
    3. Maras A,
    4. Melmed RD,
    5. Findling RL,
    6. Breddy J,
    7. et al
    . Pediatric prolonged-release melatonin for sleep in children with autism spectrum disorder: impact on child behavior and caregiver’s quality of life. J Autism Dev Disord 2019;49(8):3218-30.
    OpenUrl
PreviousNext
Back to top

In this issue

Canadian Family Physician: 66 (3)
Canadian Family Physician
Vol. 66, Issue 3
1 Mar 2020
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Melatonin for children with autism spectrum disorder
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Melatonin for children with autism spectrum disorder
Tyler Yan, Ran D. Goldman
Canadian Family Physician Mar 2020, 66 (3) 183-185;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Melatonin for children with autism spectrum disorder
Tyler Yan, Ran D. Goldman
Canadian Family Physician Mar 2020, 66 (3) 183-185;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Sleep problems with ASD
    • Melatonin
    • Low melatonin levels in ASD
    • Melatonin treatment for ASD
    • Prolonged-release melatonin
    • Conclusion
    • Notes
    • Footnotes
    • References
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Screen time and sleep in children
  • Google Scholar

More in this TOC Section

Practice

  • Determining if and how older patients can safely stay at home with additional services
  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
Show more Practice

Child Health Update

  • Accidental cannabis ingestion in young children
  • All-terrain vehicle injuries in children and adolescents
  • Screen time and sleep in children
Show more Child Health Update

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire